Leo’s Delgocitinib Cream Performs Well in Phase 3 Study of Chinese Patients With CHE
Delgocitinib cream (Anzupgo, LEO Pharma) met its primary endpoint in the Phase 3 DELTA China Trial of Chinese patients with moderate-to-severe chronic hand eczema (CHE). The primary endpoint for DELTA China was the Investigator’s Global Assessment for Chronic Hand Eczema Score (IGA-CHE TS) at Week 16, which was met with a statistically significant improvement in […]